As Abec­ma sales take off, Bris­tol My­ers and 2sev­en­ty scrap a fol­low-up CAR-T

Bris­tol My­ers Squibb and blue­bird bio spin­out 2sev­en­ty are ax­ing a CAR-T pro­gram in the wake of ris­ing Abec­ma sales.

The com­pa­nies will cease all de­vel­op­ment for the pro­gram in ques­tion, bb21217, “based on the strength of the Abec­ma clin­i­cal da­ta and high com­mer­cial in­ter­est,” 2sev­en­ty said in a press re­lease Tues­day. It’s the sec­ond an­ti-BC­MA CAR-T that Bris­tol My­ers halt­ed in the last year af­ter eject­ing a Juno-de­vel­oped pro­gram last Feb­ru­ary.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER